Innate Pharma SA

IPHA

1.800USD

-0.020-1.10%

Close 11/06, 16:00（ET）Quotes delayed by 15 min

Innate Pharma SA's Score

Industry at a Glance

Industry Ranking

287 / 501

Overall Ranking

521 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

4.750

Target Price

+161.02%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Innate Pharma SA Highlights

StrengthsRisks

Innate Pharma SA is a France-based biopharmaceutical company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. It works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. It also has a multi-product partnership with AstraZeneca.

Growing

The company is in a growing phase, with the latest annual income totaling USD 11.69M.

Fairly Valued

The company’s latest PE is -4.04, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 159.41K shares, decreasing 35.22% quarter-over-quarter.

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change

0



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

There is no valuation score for this company; the Biotechnology & Medical Research industry's average is 6.98. Its current P/E ratio is -4.04, which is -100.00% below the recent high of 0.00 and -228.73% above the recent low of -13.28.

Score

Industry at a Glance

Previous score

0.00

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 287/501

No Data

The company’s current earnings forecast score is 7.00, which is lower than the Biotechnology & Medical Research industry's average of 8.04. The average price target for Innate Pharma SA is 6.00, with a high of 11.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

7.00

Change

0

Support & Resistance

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The company’s current price momentum score is 8.79, which is higher than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 2.58 and the support level at 2.01, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.55

Change

0.24

Support & Resistance

No Data

Institutional Confidence

Currency: USD Updated: 2025-10-27

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

AllianceBernstein L.P.

60.75K

+150.33%

Morgan Stanley & Co. International Plc

51.22K

+17.69%

Citadel Advisors LLC

26.62K

+9.68%

Millennium Management LLC

11.66K

-23.91%

UBS Financial Services, Inc.

5.96K

-33.82%

GAMMA Investing LLC

2.28K

-34.00%

Rhumbline Advisers Ltd. Partnership

470.00

-30.37%

Barclays Bank PLC

307.00

--

Optiver Holding B.V.

101.00

--

Tower Research Capital LLC

--

-100.00%



1

2



There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is 0.09. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Innate Pharma SA

IPHA

3.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

CytomX Therapeutics Inc

CTMX

8.50 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.50 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Insmed Inc

INSM

8.49 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

MDGL

8.46 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Dynavax Technologies Corp

DVAX

8.41 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment